Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-PROWESS: panitumumab plus irinotecan in NeoRAS wild-type metastatic colorectal cancer
jRCTs031210565Phase 2Completed
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab and irinotecan in colorectal cancer (CRC). Primary endpoint: Objective response rate. Started Jun 2022; status: completed.
02
Drugs
panitumumabirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031210565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210565.